Autoimmune-Mediated Oxidative Stress and Endothelial Dysfunction: Implications of Accelerated Vascular Injury in Type I Diabetes

Journal of Surgical Research

Volumn 155, Issue 1, 2009, Pages 173-178

  Zimmerman, Michael A ^a   Flores, Sonia C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

atherosclerosis; autoimmunity; diabetes; oxidative stress

Indexed keywords

AUTOIMMUNITY; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; GLYCEMIC CONTROL; HUMAN; IMMUNOPATHOGENESIS; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANIMALS; ATHEROSCLEROSIS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA; INFLAMMATION; OXIDATIVE STRESS; T-LYMPHOCYTES, REGULATORY;

EID: 67349165853     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2008.04.026     Document Type: Review

References (71)

1. Nathan D.M., Meigs J., and Singer D.E. The epidemiology of cardiovascular disease in type 2 diabetes mellitus: How sweet it is or is it?. Lancet 350 (1997) SI4
2. Pyorala K., Laakso M., and Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 3 (1987) 463
3. Dorman J.S., Laporte R.E., Kuller L.H., et al. The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results. Diabetes 33 (1984) 271
4. Borch-Johnsen K., Andersen P.K., and Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 28 (1985) 590
5. Krolewski A.S., Kosinski E.J., Warram J.H., et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 59 (1987) 750
6. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 342 (2000) 381
7. Nathan D.M., Lachin J., Cleary P., et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 348 (2003) 2294
8. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005) 2643
9. Paterson A.D., Rutledge B.N., Cleary P.A., et al. The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 30 (2007) 2107
10. Kilpatrick E.S., Rigby A.S., and Atkin S.L. Mean blood glucose compared with HbA(1c) in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia 51 (2008) 365
11. Carter R.E., Lackland D.T., Cleary P.A., et al. Intensive treatment of diabetes is associated with a reduced rate of peripheral arterial calcification in the diabetes control and complications trial. Diabetes Care 30 (2007) 2646
12. Cleary P.A., Orchard T.J., Genuth S., et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes 55 (2006) 3556
13. Schaumberg D.A., Glynn R.J., Jenkins A.J., et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the diabetes control and complications trial. Circulation 111 (2005) 2446
14. Ciarla M.V., Bocciarelli A., Di Gregorio S., et al. Autoantibodies and endothelial dysfunction in well-controlled, uncomplicated insulin-dependent diabetes mellitus patients. Atherosclerosis 158 (2001) 241
15. Petty R.G., Pottinger B.E., Greenwood R.M., et al. Diabetes is associated with a high incidence of endothelial-binding antibodies which do not correlate with retinopathy, von Willebrand factor, angiotensin-converting enzyme or C-reactive protein. Diabetes Res 17 (1991) 115
16. Wangel A.G., Kontiainen S., Scheinin T., et al. Anti-endothelial cell antibodies in insulin-dependent diabetes mellitus. Clin Exp Immunol 88 (1992) 410
17. Pomilio M., Mohn A., Verrotti A., et al. Endothelial dysfunction in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 15 (2002) 343
18. Wautier M.P., Chappey O., Corda S., et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol 280 (2001) E685
19. Mullarkey C.J., Edelstein D., and Brownlee M. Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173 (1990) 932
20. Du X.L., Edelstein D., Rossetti L., et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97 (2000) 12222
21. Nishikawa T., Edelstein D., Du X.L., et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404 (2000) 787
22. Aird W.C. Endothelium as an organ system. Crit Care Med 32 (2004) S271
23. Aird W.C. Endothelium and allotransplantation. Transplantation 82 (2006) S6
24. Nicolls M.R., Haskins K., and Flores S.C. Oxidant stress, immune dysregulation, and vascular function in type I diabetes. Antioxid Redox Signal 9 (2007) 879
25. Inoue T., and Node K. Vascular failure: A new clinical entity for vascular disease. J Hypertens 24 (2006) 2121
26. Zimmerman M.A., Selzman C.H., Cothren C., et al. Diagnostic implications of C-reactive protein. Arch Surg 138 (2003) 220
27. Berk B.C., Weintraub W.S., and Alexander R.W. Elevation of C-reactive protein in "active" coronary artery disease. Am J Cardiol 65 (1990) 168
28. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331 (1994) 417
29. Toss H., Lindahl B., Siegbahn A., et al. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 96 (1997) 4204
30. Harris T.B., Ferrucci L., Tracy R.P., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106 (1999) 506
31. Danesh J., Whincup P., Walker M., et al. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 321 (2000) 199
32. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973
33. Pasceri V., Cheng J.S., Willerson J.T., et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103 (2001) 2531
34. Torzewski M., Rist C., Mortensen R.F., et al. C-reactive protein in the arterial intima: Role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscl Throm Vasc Biol 20 (2000) 2094
35. Chase H.P., Cooper S., Osberg I., et al. Elevated C-reactive protein levels in the development of type 1 diabetes. Diabetes 53 (2004) 2569
36. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813
37. Piganelli J.D., Flores S.C., Cruz C., et al. A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T-cell clone. Diabetes 51 (2002) 347
38. Ling X., Cota-Gomez A., Flores N.C., et al. Alterations in redox homeostasis and prostaglandins impair endothelial-dependent vasodilation in euglycemic autoimmune nonobese diabetic mice. Free Rad Biol Med 39 (2005) 1089
39. Kaneto H., Kajimoto Y., Miyagawa J., et al. Beneficial effects of antioxidants in diabetes: Possible protection of pancreatic beta-cells against glucose toxicity. Diabetes 48 (1999) 2398
40. Lenzen S., Drinkgern J., and Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Rad Biol Med 20 (1996) 463
41. Matsuoka H. Endothelial dysfunction associated with oxidative stress in human. Diab Res Clin Prac 54 (2001) S65
42. Griendling K.K., Sorescu D., and Ushio-Fukai M. NAD(P)H oxidase: Role in cardiovascular biology and disease. Circ Res 86 (2000) 494
43. Lassegue B., and Clempus R.E. Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285 (2003) R277
44. Higuchi M., Ishizu A., Ikeda H., et al. Functional alteration of peripheral CD25(+)CD4(+)immunoregulatory T cells in a transgenic rat model of autoimmune diseases. J Autoimmunity 20 (2003) 43
45. Sakaguchi S., Takahashi T., and Nishizuka Y. Study on cellular events in post-thymectomy autoimmune oophoritis in mice. II. Requirement of Lyt-1 cells in normal female mice for the prevention of oophoritis. J Exp Med 156 (1982) 1577
46. Nishizuka Y., and Sakakura T. Thymus and reproduction: sex-linked dysgenesia of the gonad after neonatal thymectomy in mice. Science 16 (1969) 753
47. Bennett C.L., Christie J., Ramsdell F., et al. The immune dysregulation, polyendocrinopathy, enteropathy. X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27 (2001) 20
48. Wildin R.S., Ramsdell F., Peake J., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet 27 (2001) 18
49. Brunkow M.E., Jeffery E.W., Hjerrild K.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 27 (2001) 68
50. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The Diabetes Control and Complications Trial Research Group. Ann Int Med 128 (1998) 517
51. Staeva-Vieira T., Peakman M., and von Herrath M. Translational mini-review series on type 1 diabetes: Immune-based therapeutic approaches for type 1 diabetes. Clin Exp Immunol 148 (2007) 17
52. Wagner Jr. D.H., Vaitaitis G., Sanderson R., et al. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc Natl Acad Sci USA 99 (2002) 3782
53. Waid D.M., Vaitaitis G.M., and Wagner Jr. D.H. Peripheral CD4loCD40+ auto-aggressive T cell expansion during insulin-dependent diabetes mellitus. Euro J Immunol 34 (2004) 1488
54. Mach F., Schonbeck U., and Libby P. CD40 signaling in vascular cells: a key role in atherosclerosis?. Atherosclerosis 137 (1998) S89
55. Balasa B., Krahl T., Patstone G., et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 159 (1997) 4620
56. Cipollone F., Chiarelli F., Davi G., et al. Enhanced soluble CD40 ligand contributes to endothelial cell dysfunction in vitro and monocyte activation in patients with diabetes mellitus: Effect of improved metabolic control. Diabetologia 48 (2005) 1216
57. Anderson M.S., and Bluestone J.A. The NOD mouse: a model of immune dysregulation. Ann Rev Immunol 23 (2005) 447
58. Eisenbarth G.S., Srikanta S., Jackson R., et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 2 (1985) 271
59. Bougneres P.F., Landais P., Boisson C., et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 39 (1990) 1264
60. Herold K.C., Hagopian W., Auger J.A., et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 346 (2002) 1692
61. Herold K.C., Gitelman S.E., Masharani U., et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 54 (2005) 1763
62. Keymeulen B., Vandemeulebroucke E., Ziegler A.G., et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 352 (2005) 2598
63. Mallat Z., Ait-Oufella H., and Tedgui A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc Med 17 (2007) 113
64. Goronzy J.J., and Weyand C.M. Immunosuppression in atherosclerosis: mobilizing the opposition within. Circulation 114 (2006) 1901
65. Ait-Oufella H., Salomon B.L., Potteaux S., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12 (2006) 178
66. Gotsman I., Grabie N., Gupta R., et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114 (2006) 2047
67. Heller E.A., Liu E., Tager A.M., et al. Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells. Circulation 113 (2006) 2301
68. Mor A., Planer D., Luboshits G., et al. Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscl Thromb Vasc Biol 27 (2007) 893
69. Steffens S., Burger F., Pelli G., et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 114 (2006) 1977
70. van Puijvelde G.H., Hauer A.D., de Vos P., et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114 (2006) 1968
71. de Boer O.J., van der Meer J.J., Teeling P., et al. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. PLoS ONE 2 (2007) e779